Inclusion Criteria:

• The subject must be >=18 years of age.(Phase 1 & 2a)
• Histologically documented diagnosis of small cell lung cancer (North America & UK) or other non-hematological malignancy (North America only).(Ph1)
• Histologically documented diagnosis of SCLC.(Ph2a)
• At least one prior chemotherapy treatment regimen(s) and their disease is refractory or experienced progressive disease following the treatment. (Ph1)
• Extensive-stage SCLC & is chemotherapy naïve(US only) has experienced progressive disease following at least one chemotherapy regimen or their disease is refractory.(Ph2a)
• Brain metastases with clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of stable neurologic function & no evidence of CNS disease progression as determined by CT or MRI within 21 days prior to the first dose of study drug.
• ECOG performance score <= 2(Ph 1) <=1(Ph 2a)
• Must be receiving a stable dose of Selective Serotonin Reuptake Inhibitor (SSRI) anti-depressants (e.g. Prozac)21 days prior to 1st dose of study drug.

• Adequate bone marrow, renal & hepatic function per local lab reference range at Screening as follows:

  • Bone marrow: Absolute Neutrophil count (ANC)>=1000/µL
  • Platelets>= 100,000/mm3
  • Hemoglobin>=9.0g/dL
  • Renal function: Serum creatinine<= 2.0mg/dL or calculated creatinine clearance>=50mL/min
  • Hepatic function&enzymes: AST and ALT<=3.0 x the upper normal limit(ULN) of institution's normal range
  • Bilirubin<=1.5xULN. If Gilbert's Syndrome may have Bilirubin> 1.5 x ULN
  • Coagulation: aPTT and PT<=1.2 x the upper limit of normal
• Should have archived diagnostic tissue available for assessment of Bcl-2 family protein expression.(Pha 2a)

• Surgically sterile postmenopausal(for at least one year) or a negative pregnancy test performed as follows:

  • At Screening on a serum sample obtained within 14 days prior to initial study drug administration, and
  • Prior to dosing on a urine sample obtained on Cycle 1 Day-3.

• All female subjects not surgically sterile or postmenopausal(for at least 1 year)and non-vasectomized male subject must practice at least one of the following methods for birth control:

  • Total abstinence from sexual intercourse (minimum one complete menstrual cycle)
  • A vasectomized partner; hormonal contraceptives (oral, parenteral or transdermal) for at least three months prior to study drug administration
  • Double-barrier method(including condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream)
• Subject, or legal representative voluntarily sign & date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.

Exclusion Criteria:

• Underlying or predisposing condition of bleeding or currently exhibits signs of bleeding. Recent history of non-chemotherapy induced thrombocytopenia associated bleeding within 1 year prior to first dose of study drug.
• Active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis.
• History of platelet autoantibodies or autoimmune phenomena including immune thrombocytopenic purpura (ITP) or autoimmune hemolytic anemia (AIHA).
• Currently receiving or requires anticoagulation therapy or any drug or herbal supplements that affect platelet function, with exception of low-dose anticoagulation medications that are used to maintain the patency of a central intravenous catheter.
• Received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal (with the exception of hormones for hypothyroidism or estrogen replacement or erythropoietin), or any investigational therapy within 14 days prior to the first dose of study drug, or has not recovered to less than a grade 2 clinically significant adverse effect(s)/toxicity(s) of the previous therapy.
• Has consumed grapefruit or grapefruit products within 3 days prior to the first dose of study drug.
• Significant history of cardiovascular disease (e.g., MI, thrombotic or thromboembolic event in the last 6 months), renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease that in the opinion of the investigator would adversely affect his/her participating in this study. Questions regarding inclusion of individual subjects should be directed to Abbott Medical Monitor or designee.
• Pregnant or breast-feeding.
• Positive for HIV (due to potential drug-drug interactions and potential effects on lymphocytes).

• Previous or current malignancies at other sites, with the exception of:

  • Adequately treated in situ carcinoma of the cervix uteri; basal or squamous cell carcinoma of the skin
  • Previous malignancy (e.g. localized prostate cancer)confined and surgically resected with no evidence of disease within three years.

• Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:

  • Active systemic fungal infection
• Diagnosis of fever and neutropenia within 1 week prior to study drug administration.
• Subject received aspirin within seven days prior to the first dose of study drug.
• Subject received steroid therapy within seven days prior to the first dose of study drug with the exception of inhaled steroids for asthma, topical steroids, or replacement/stress corticosteroids.